{"entity":{"type":"insider","cik":"0001554593","url":"/insider/0001554593","json_url":"/insider/0001554593.json","name":"Latkin Jed","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":10,"n_filings":6,"first":"2017-05-23","last":"2020-02-20","span_basis":"filed_date"},"name_variants":[{"name":"Latkin Jed","source":"filing","n_filings":6,"first_seen":"2017-05-23","last_seen":"2020-02-20"}],"transactions":[{"id":3060610,"accession":"0001437749-20-003172","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001437749-20-003172","line_url":"/filing/0001437749-20-003172#line-1","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":"0001554593","owner_name":"Latkin Jed","owner_display_name":"Latkin Jed","owner_url":"/insider/0001554593","role":"Director, Officer (CEO, COO & CFO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, COO & CFO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":1.08,"price_display":"1.08","price_state":"stated","total_value":5400.0,"total_display":"5,400.00","total_whole":"5,400","shares_owned_after":17950.0,"shares_owned_after_display":"17,950","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-20","filed_date":"2020-02-20","scope":"insider"},{"id":8503474,"accession":"0001437749-19-011608","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001437749-19-011608","line_url":"/filing/0001437749-19-011608#line-1","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":"0001554593","owner_name":"Latkin Jed","owner_display_name":"Latkin Jed","owner_url":"/insider/0001554593","role":"Director, Officer (CEO, COO & CFO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, COO & CFO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":1.2583,"price_display":"1.26","price_state":"stated","total_value":1258.3,"total_display":"1,258.30","total_whole":"1,258","shares_owned_after":12950.0,"shares_owned_after_display":"12,950","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-06-05","filed_date":"2019-06-07","scope":"insider"},{"id":7961007,"accession":"0001437749-19-010383","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001437749-19-010383","line_url":"/filing/0001437749-19-010383#line-2","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":"0001554593","owner_name":"Latkin Jed","owner_display_name":"Latkin Jed","owner_url":"/insider/0001554593","role":"Director, Officer (CEO, COO & CFO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, COO & CFO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":1.4629,"price_display":"1.46","price_state":"stated","total_value":1462.9,"total_display":"1,462.90","total_whole":"1,463","shares_owned_after":11950.0,"shares_owned_after_display":"11,950","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-17","filed_date":"2019-05-17","scope":"insider"},{"id":7961004,"accession":"0001437749-19-010383","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001437749-19-010383","line_url":"/filing/0001437749-19-010383#line-1","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":"0001554593","owner_name":"Latkin Jed","owner_display_name":"Latkin Jed","owner_url":"/insider/0001554593","role":"Director, Officer (CEO, COO & CFO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, COO & CFO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1500.0,"shares_display":"1,500","price_per_share":1.4536,"price_display":"1.45","price_state":"stated","total_value":2180.4,"total_display":"2,180.40","total_whole":"2,180","shares_owned_after":10950.0,"shares_owned_after_display":"10,950","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-16","filed_date":"2019-05-17","scope":"insider"},{"id":7795393,"accession":"0001437749-19-010054","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001437749-19-010054","line_url":"/filing/0001437749-19-010054#line-3","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":"0001554593","owner_name":"Latkin Jed","owner_display_name":"Latkin Jed","owner_url":"/insider/0001554593","role":"Director, Officer (CEO, COO & CFO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, COO & CFO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":1.4477,"price_display":"1.45","price_state":"stated","total_value":1447.7,"total_display":"1,447.70","total_whole":"1,448","shares_owned_after":9450.0,"shares_owned_after_display":"9,450","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-15","filed_date":"2019-05-15","scope":"insider"},{"id":7795392,"accession":"0001437749-19-010054","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001437749-19-010054","line_url":"/filing/0001437749-19-010054#line-2","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":"0001554593","owner_name":"Latkin Jed","owner_display_name":"Latkin Jed","owner_url":"/insider/0001554593","role":"Director, Officer (CEO, COO & CFO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, COO & CFO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":1.8396,"price_display":"1.84","price_state":"stated","total_value":3679.2,"total_display":"3,679.20","total_whole":"3,679","shares_owned_after":8450.0,"shares_owned_after_display":"8,450","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-14","filed_date":"2019-05-15","scope":"insider"},{"id":7795390,"accession":"0001437749-19-010054","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001437749-19-010054","line_url":"/filing/0001437749-19-010054#line-1","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":"0001554593","owner_name":"Latkin Jed","owner_display_name":"Latkin Jed","owner_url":"/insider/0001554593","role":"Director, Officer (CEO, COO & CFO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, COO & CFO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2400.0,"shares_display":"2,400","price_per_share":1.9144,"price_display":"1.91","price_state":"stated","total_value":4594.56,"total_display":"4,594.56","total_whole":"4,595","shares_owned_after":6450.0,"shares_owned_after_display":"6,450","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-13","filed_date":"2019-05-15","scope":"insider"},{"id":4824144,"accession":"0001654954-17-005235","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001654954-17-005235","line_url":"/filing/0001654954-17-005235#line-1","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":"0001554593","owner_name":"Latkin Jed","owner_display_name":"Latkin Jed","owner_url":"/insider/0001554593","role":"Officer (COO and CFO)","role_mark":"O","role_mark_label":"Officer (COO and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"COO and CFO","security_title":"Common Stock, $.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7600.0,"shares_display":"7,600","price_per_share":0.4364,"price_display":"0.44","price_state":"stated","total_value":3316.64,"total_display":"3,316.64","total_whole":"3,317","shares_owned_after":50159.0,"shares_owned_after_display":"50,159","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-05-30","filed_date":"2017-05-31","scope":"insider"},{"id":4714889,"accession":"0001654954-17-005032","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001654954-17-005032","line_url":"/filing/0001654954-17-005032#line-2","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":"0001554593","owner_name":"Latkin Jed","owner_display_name":"Latkin Jed","owner_url":"/insider/0001554593","role":"Officer (COO and CFO)","role_mark":"O","role_mark_label":"Officer (COO and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"COO and CFO","security_title":"Common Stock, $.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11200.0,"shares_display":"11,200","price_per_share":0.4499,"price_display":"0.45","price_state":"stated","total_value":5038.88,"total_display":"5,038.88","total_whole":"5,039","shares_owned_after":42559.0,"shares_owned_after_display":"42,559","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-05-22","filed_date":"2017-05-23","scope":"insider"},{"id":4714886,"accession":"0001654954-17-005032","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001654954-17-005032","line_url":"/filing/0001654954-17-005032#line-1","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":"0001554593","owner_name":"Latkin Jed","owner_display_name":"Latkin Jed","owner_url":"/insider/0001554593","role":"Officer (COO and CFO)","role_mark":"O","role_mark_label":"Officer (COO and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"COO and CFO","security_title":"Common Stock, $.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14159.0,"shares_display":"14,159","price_per_share":0.4511,"price_display":"0.45","price_state":"stated","total_value":6387.1249,"total_display":"6,387.12","total_whole":"6,387","shares_owned_after":31359.0,"shares_owned_after_display":"31,359","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-05-19","filed_date":"2017-05-23","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":10,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":10,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":10},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000810509","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","url":"/issuer/0000810509","role":"Director, Officer (CEO, COO & CFO)","n_filings":6,"first_seen":"2017-05-23","last_seen":"2020-02-20"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001554593","retrieved_at":"2026-08-26T17:50:43+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}